Skip to main content

U.K. MS Patients Report Quality Of Life Improvements Following Cannabis Therapy

doctor doctors office health medical

Multiple sclerosis (MS) is a serious health condition that impacts the lives of many suffering patients around the globe. It is estimated that as many as 2.8 million people suffer from MS worldwide and that a person is diagnosed somewhere on the planet with the health condition every 5 minutes.

MS is a progressive disease involving damage to the sheaths of nerve cells in the brain and spinal cord. Symptoms can include but are not limited to, numbness, impaired speech, impaired muscular coordination, blurred vision, and severe fatigue.

Studies and personal experiences around the world have found that cannabis may be a helpful form of treatment for MS patients. A growing list of patients have reported that cannabis helps them effectively and safely treat their condition.

According to a recent study in the United Kingdom, MS patients reported improvements in their quality of life after completing cannabis therapies. Below is more information about it via a news release from NORML:

London, United Kingdom: Multiple sclerosis (MS) patients report improvements in their health-related quality of life following the use of medical cannabis preparations, according to observational data published in the journal Multiple Sclerosis and Related Disorders.

British researchers assessed the use of cannabis-based medicinal products (CBMPs) consisting of either flower or oil extracts in 141 MS patients enrolled in the UK Medical Cannabis Registry. (Since 2018, British specialists have been permitted to prescribe cannabis-based medicinal products to patients unresponsive to conventional medications.) Researchers assessed changes in patient-reported outcomes measures at one month, three months, and six months.

Patients reported sustained improvements in their physical and mental health following cannabis therapy. They reported few serious adverse health effects during treatment.

“This case series demonstrates a potential association between [the] initiation of CBMPs and improved patient reported outcomes in sleep, anxiety and general HRQoL [health-related quality of life] measures, over six months,” the study’s authors concluded. “Additional measures for HRQoL, including various physical and mental health subdomains, also exhibit improvements up to six months when compared to baseline.”

A prescription cannabis spray (nabiximols aka Sativex) consisting of specific ratios of THC and CBD is currently available in several countries, including Canada, France, Germany, Spain, and the United Kingdom. The drug is not approved in the United States for treatment of any condition.
Full text of the study, “Clinical outcome analysis of patients with multiple sclerosis – Analysis from the UK Medical Cannabis Registry,” appears in Multiple Sclerosis and Related DisordersAdditional information on cannabis and multiple sclerosis is available from NORML’s publication, Clinical Applications for Cannabis & Cannabinoids.

United Kingdom